AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Amneal Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$19.36+0.18 (+0.94%)
Close on Oct 19, 2026
- Market cap
- $6.35B
- P/E (TTM)
- 39.5
- Dividend yield
- –
Amneal Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | $489.91M | $423.24M | $436.65M | $460.74M | $433.43M | $414.71M | $439.30M | $427.35M | $427.33M | $391.29M | – | – | 61.5% | +13.0% |
| AvKARE | $156.99M | $166.02M | $210.74M | $198.53M | $163.04M | $172.42M | $170.39M | $159.49M | $170.41M | $162.66M | $149.46M | $131.88M | 19.7% | -3.7% |
| Specialty | $149.30M | $133.27M | – | $125.24M | $128.04M | $108.30M | – | $115.64M | $104.04M | $105.23M | – | $97.30M | 18.8% | +16.6% |
| Specialty | $149.30M | – | $166.93M | $125.24M | $128.04M | $108.30M | $120.84M | $115.64M | $104.04M | $105.23M | $104.48M | $97.30M | 18.8% | +16.6% |
| Affordable Medicines | – | – | – | – | – | – | – | $427.35M | $427.33M | $391.29M | $363.04M | $390.86M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | $123.08M | $120.94M | $82.00M | $85.63M | $102.38M | $110.79M | $91.90M | $88.30M | $101.31M | -$11.40M | – | – | +20.2% |
| Specialty | $54.86M | $50.06M | – | $9.57M | $35.49M | $14.99M | – | $32.42M | $26.85M | $29.24M | – | $18.60M | +54.6% |
| AvKARE | $9.34M | $22.40M | $25.53M | $27.03M | $18.15M | $12.91M | $7.46M | $13.11M | $10.98M | $11.35M | $9.12M | $11.88M | -48.6% |
| Affordable Medicines | – | – | – | – | – | – | – | $88.30M | $101.31M | -$11.40M | $46.95M | $87.45M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Amneal Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.